{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12"],"submitter":["Ji S"],"pubmed_abstract":["Human babesiosis is a global emerging tick-borne disease caused by infection with intra-erythrocytic parasites of the genus <i>Babesia</i>. With the rise in human babesiosis cases, the discovery and development of new anti-<i>Babesia</i> drugs are essential. Phosphatidylinositol 4-kinase (PI4K) is a widely present eukaryotic enzyme that phosphorylates lipids to regulate intracellular signaling and trafficking. Previously, we have shown that MMV390048, an inhibitor of PI4K, showed potent inhibition against <i>Babesia</i> species, revealing PI4K as a druggable target for babesiosis. However, twice-administered, 7-day regimens failed to clear <i>Babesia microti</i> parasites from the immunocompromised host. Hence, in this study, we wanted to clarify whether targeting PI4K has the potential fo"],"journal":["Frontiers in cellular and infection microbiology"],"pagination":["1048962"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9701728"],"repository":["biostudies-literature"],"pubmed_title":["Phosphatidylinositol 4-kinase is a viable target for the radical cure of <i>Babesia microti</i> infection in immunocompromised hosts."],"pmcid":["PMC9701728"],"pubmed_authors":["Ji S","Asada M","Liu M","Yanagawa M","Xuan X","Zafar I","Galon EM","Amer MM","Zhou J"],"additional_accession":[]},"is_claimable":false,"name":"Phosphatidylinositol 4-kinase is a viable target for the radical cure of <i>Babesia microti</i> infection in immunocompromised hosts.","description":"Human babesiosis is a global emerging tick-borne disease caused by infection with intra-erythrocytic parasites of the genus <i>Babesia</i>. With the rise in human babesiosis cases, the discovery and development of new anti-<i>Babesia</i> drugs are essential. Phosphatidylinositol 4-kinase (PI4K) is a widely present eukaryotic enzyme that phosphorylates lipids to regulate intracellular signaling and trafficking. Previously, we have shown that MMV390048, an inhibitor of PI4K, showed potent inhibition against <i>Babesia</i> species, revealing PI4K as a druggable target for babesiosis. However, twice-administered, 7-day regimens failed to clear <i>Babesia microti</i> parasites from the immunocompromised host. Hence, in this study, we wanted to clarify whether targeting PI4K has the potential fo","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-19T22:48:47.856Z","creation":"2025-04-19T22:48:47.856Z"},"accession":"S-EPMC9701728","cross_references":{"pubmed":["36452305"],"doi":["10.3389/fcimb.2022.1048962"]}}